Status:
UNKNOWN
Clinical Outcome of Patients With Resistant Hypertension Undergoing Renal Denervation
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Hypertension, Renal
Eligibility:
All Genders
Brief Summary
Studies on the impact of RDN on cardiovascular surrogate markers have shown a variety of beneficial effects: RDN is associated with a decrease blood pressure (BP), left ventricular mass (LVM), a reduc...
Detailed Description
Two registries interlinked by the Swedish personal identification number The Swedish Registry for Renal Denervation: The Swedish Registry for Renal Denervation is an investigator - initiated academic ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients registered in the Swedish Registry for Renal Denervation or SPCCD, fulfilling the criteria for resistant hypertension according to the criteria as applied in the Swedish Registry for Renal Denervation (Office BP \>140/90 despite treatment with at least three antihypertensive drugs).
- Exclusion criteria:
- Any patient who has withdrawn consent from being in either registry.
Exclusion
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04722159
Start Date
February 1 2021
End Date
August 1 2021
Last Update
January 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sahlrenska University Hospital
Gothenburg, Sweden, 41345